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The effect of early measles vaccination at
4.5 months of age on growth at 9 and
24 months of age in a randomized trial in
Guinea-Bissau
S. M. Rasmussen1,2, S. Biering-Sørensen1,2, S. Byberg1,2,3, A. Andersen1,2, M. Bjerregaard-Andersen1,2,4, A. Rodrigues1,
C. S. Benn1,2,3*, C. L. Martins1 and P. Aaby1,2
Abstract
Background: Providing an early, additional measles vaccine (MV) at 4.5 months of age has been shown to reduce
child mortality in low-income countries. We studied the effects on growth at 9 and 24 months of age.
Methods: A randomized controlled trial was conducted in Guinea-Bissau from 2003–2007 including 6,648 children.
Children were randomized 1:1:1 to receive Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age (group
A), no vaccine at 4.5 months and Edmonston-Zagreb measles vaccine at 9 months (group B), or no vaccine at 4.
5 months and Schwarz measles vaccine at 9 months (group C) Data on anthropometrics were obtained at enrolment
at 4.5 months of age and again at 9 and 24 months of age. Analyses were stratified by sex, season of enrolment, and
neonatal vitamin A supplementation (NVAS) status, as all these factors have been shown to modify the effect of early
MV on mortality.
Results: Overall there was no effect of early MV on anthropometry at 9 months. At 24 months children who
had received early MV had a significantly larger mid-upper-arm-circumference (MUAC/in cm) (Difference = 0.08;
95% CI (0.02;0.14)) compared with children in the control group; this effect was most pronounced among
girls (0.12 (0.03;0.20)). The effect of early MV on MUAC remained significant in the dry season and in girls
who received placebo rather than NVAS.
Conclusion: Early MV was associated with a larger MUAC particularly in girls. These results indicate that a
two-dose measles vaccination schedule might not only reduce child mortality but also improve growth.
Trial registration: ClinicalTrials.gov NCT00168558. Registered September 9, 2005, retrospectively registered
Keywords: Early measles vaccination, Growth, Non-specific effects, Sex-differential effects, Neonatal vitamin A
supplementation, Season
Background
When the measles vaccine (MV) was introduced in high
mortality areas in Africa in the 1970s, studies reported
mortality declines of 40% or more [1–6]. A decrease in
mortality of this magnitude cannot be explained merely
by prevention of measles cases and its long-term conse-
quences, since measles deaths accounts for an estimated
10% of all deaths among under-5-years-olds [7]. Thus it
has been suggested that MV may have beneficial
heterologous or non-specific effects on the susceptibility
to infectious diseases other than measles [3, 5, 8].
In low-income countries, the World Health Organization
(WHO) recommends that children are vaccinated against
measles at 9 months of age, to ensure protection as early
in life as possible and at the same time minimizing interfer-
ence from maternal antibodies (MA) [9]. In 2003–2007,
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the Bandim Health Project in Guinea-Bissau conducted a
large randomized trial, the “Early MV trial”, to explore the
potential benefits of providing an additional early MV [8].
In this trial children were randomized to receive two doses
of MV at 4.5 months and at 9 months or only one dose of
MV at 9 months of age [9]. The study found a beneficial
effect of the two-dose regimen on mortality and hospi-
talizations [8, 10]. In the per-protocol analysis the mor-
tality rate ratio (MRR) of children who received two
doses of MV compared with one dose only was 0.70
(95% CI 0.52;0.94) between 4.5 and 36 months of age.
The effect was significant for girls, when stratifying by
sex. A large proportion (57%) of the children enrolled
in the Early MV trial had previously participated in a
trial of neonatal vitamin A supplementation at birth
(NVAS) [11], [12]. Interestingly, NVAS seemed to
modify the effect of early MV [8, 10]; early MV was
not associated with mortality reductions in children
who received NVAS, but only children who did not
receive NVAS. The effect of an early MV on hospitaliza-
tions was also explored within this study, and early MV
was found to reduce the rates of hospital admissions,
especially admissions for respiratory infections [10]. Dry
(December-May) vs. rainy (June-November) season were
also found to influence the effect of MV on mortality [8].
The aim of the present study was to explore the effect of
early MV on growth within the children enrolled in the
“Early MV trial”. We pre-specified that we would explore
whether sex and (NVAS), along with season, modified the
effect of early MV on growth.
Methods
Setting
The early MV trial was conducted from 2003–2007 in
Bissau, the capital of Guinea-Bissau, where the Bandim
Health Project (BHP) has maintained a health and
demographic surveillance system (HDSS) since 1978.
The HDSS catchment area covers an area of 102,000
inhabitants divided into six different districts. All
children less than three years of age are visited every
three months at their home and various information is
collected, including information on family conditions,
hospital admissions, sickness and vital status [8]. At time
of study, the routine vaccination schedule was BCG and
oral polio vaccine (OPV) at birth, diphtheria, tetanus,
pertussis (DTP) + OPV at 6,10 and 14 weeks and measles
and yellow fever vaccines at 9 months of age. [8] The
infant mortality rate was 138 per 1,000 live births, and
the under-five mortality rate was 223 per 1,000 live
births, the main causes of deaths being malaria, acute
respiratory infections and diarrhea. An estimated 4% of
the children were malnourished and 19% suffered from
moderate malnutrition [13]. There was a measles out-
break in the early phase of the trial, from October 2003
to May 2004; 100 participants were diagnosed with mea-
sles. Apart from that, there was no circulating measles [8].
In the present study, children 4.5 to 7 months of age,
residing within the study area were invited to participate.
Children were only included if a minimum of 4 weeks
since the third diphtheria, tetanus, pertussis (DTP) vac-
cine had passed. Oral and written explanations of the
study were provided to the mother/guardian. Mothers/
guardians willing to let their children participate signed
a consent form by signature or fingerprint if illiterate.
The children were individually randomized 1:1:1 into
three groups; the first group received early Edmonston-
Zagreb MV at 4.5 months of age and again at 9 months
of age (Group A), the second group received no vaccine
at 4.5 months and Edmonston-Zagreb MV at 9 months
(Group B), and the third group received no vaccine at
4.5 months and Schwarz MV at 9 months (Group C).
For ethical reasons, no placebo was given in groups B
and C at 4.5 months. If the mother moved away from
the study area with the child and had received a placebo
vaccine at 4.5 months, we feared that the mother would
mistakenly think the child was already measles vaccinated
and therefore not take the child to measles vaccination at
9 months. The staff assessing outcomes were unaware
of the child’s vaccination status and were instructed not
to ask the mother if the child had received an early MV
or not.
The study design has been described in detail else-
where [8]. Children included in the study visited the
health center on three occasions: at inclusion, at
9 months and 24 months of age. The children in group
B and C also visited the health center at 18 months,
where they were randomized to an additional dose of
MV. Severe adverse events were monitored through
surveillance of hospital admissions [10] and of mortality
[8] for both outcomes the early MV group had less
severe events.
Growth
Anthropometric measurements were conducted by
trained field assistants at each visit to the health center;
at inclusion, 9 and 24 months (No measurements were
obtained by the end of follow-up at 36 months of age).
Growth was assessed by measuring length, weight and
middle-upper arm circumference (MUAC). Weight of
the undressed child was measured by an electronic scale
(SECA 336) to the nearest 0.01 kg while the child was
lying or sitting. Length was measured (SECA 416) while
the child was lying down. MUAC was measured with a
non-stretch TALC tape on the upper left arm in mm.
Hypotheses and statistical analysis
All statistical analyses were conducted in STATA 11.
Length and weight were converted to Z-scores using
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WHO 2006 standards; lenght-for-age, weight-for-age
and weight-for-length [14]. MUAC was not converted to
Z-score as the recommendation for MUAC cutoffs is
not valid for children under 6 months of age [14, 15].
Furthermore, we have found that MUAC is as good a
predictor of mortality as MUAC z-score [16].
The analysis of mortality had found no differences in
mortality rates according to type of vaccine (Edmonston-
Zagreb MV (Group B) or Schwarz MV (Group C)); we
likewise found no difference in growth rates according to
type of vaccine, and therefore combined the groups. By
18 months of age, the children in groups B and C were
furthermore randomized to an additional MV or no
additional MV. We found no effect of the additional
MV (data not shown) and therefore combined the two
groups. Thus, the present analysis focusses on the effect
of receiving an early MV at 4.5 months of age (Group A)
versus no early MV (Groups B and C).
We used linear regression to analyze the anthropometric
outcomes at 9 and 24 months of age. All analyses were ad-
justed for the baseline measurement at 4.5 months of age.
Potential deviations from linearity were assessed. We
constructed scatterplots of the residuals to check for
normal distribution, to ensure the assumptions of the
model.
We had specified in the protocol that we would stratify
our analysis by sex and season. Furthermore, we stratified
by NVAS as we had observed interaction between Early
MV and NVAS with respect to mortality [8, 17].
We conducted a large number of tests increasing the
risk of chance findings. To control for multiple testing
we conducted permutation tests [18] in the main ana-
lysis and in each of the pre-specified subgroup analyses
(For further descriptions see Additional file 1).
Sample size
The study size was based on the main outcome mortal-
ity. With 6000 children and a mean MUAC of 14.55 cm
(SD = 1.3 cm) by 9 months of age, we would be able to
show a difference of 0.1 cm in MUAC with a power of
80% and a significance level of 0.05.
Results
A total of 6648 children were enrolled in the main trial
between August 2003 and April 2007 (Fig. 1). The partici-
pant flow has been described in detail elsewhere [8]; 6,417
children were randomized, 2129 to receive MV at
4.5 months and 9 months (intervention group) and 4288
were randomized to MV at 9 months of age only (control
group). A total of 1960 (92%) children from the interven-
tion group and 3666 (85%) from the control group were
seen at the health center at 9 months. At 24 months, this
was 1475 (69%) and 2777 (65%), respectively.
There were no differences in demographic, socioeco-
nomic or health related background factors between the
children in the two randomization groups (Additional file
2: Table S1). Demographic, socioeconomic or health related
factors were also similar for children in the two groups who
were lost to follow-up at 9 months and 24 months
(Additional file 3: Table S2, Additional file 4: Table S3).
Anthropometry
At 9 months of age, there were no significant differences
in MUAC or in z-scores of weight-for-age and length-
for-age between the two randomization groups neither
overall nor when stratified on sex, season and NVAS
(Table 1 and Additional file 5: Figure S1).
At 24 months of age, early MV was associated with sig-
nificantly larger MUAC overall (0.08; 95%CI:0.02;0.14).
This effect was significant in girls (0.12(0.03;0.20)) but not
in boys (Table 1). The effect of early MV on MUAC in
girls was significant in the dry season (0.15(0.02;0.27)).
Among girls who received placebo in the NVAS trial the
effect of early MV on MUAC was furthermore significant
(0.18(0.03;0.33)) (Fig. 2). No effects were seen on weight-
for-age and length-for-age at 24 months.
When controlling for multiple testing using the permuta-
tion test, we found that the effect on MUAC at 24 months
was still significantly larger in the intervention group. Fur-
thermore, the effect on girls’ MUAC at 24 months overall
and in the subgroup who did not receive NVAS at birth
remained significant. However, when adjusting for multiple
testing, the effect on MUAC at 24 months among girls
included in the dry season was no longer significant.
Discussion
There were no overall consistent effects of early MV on
growth. However, we saw a positive effect on MUAC at
24 months of age. This effect was most pronounced
among girls, especially those enrolled during the dry season
and those who received placebo at birth.
Strengths and weaknesses
The major strength of this study is the randomized
design, as well as the large number of study participants.
In Bissau, there is in general a large migration in and
out of the study area. However at 9 months only 12%
(intervention 8%; control 14%) were lost to follow up
(FU), but there was an imbalance when comparing the
two randomization groups, as more children in the con-
trol group had received MV elsewhere and were there-
fore excluded from the analysis, because the time of
vaccine, vaccine strain and quality of the MV was un-
known. Assuming that these unknown MV vaccinations
in the 9 months MV group also had a beneficial effect,
they would have lowered the difference in MUAC and
reduced the estimated beneficial effect of early MV
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between 4.5 and 24 months of age. However among chil-
dren excluded there were no baseline differences. At
24 months 21% were lost to FU (intervention 23%, con-
trol 20%), mainly because they were travelling or had
moved during the study period. Furthermore there were
no baseline differences between the groups of children
lost to FU. Nonetheless, it clearly reduced our power,
because of an expected 10% lost to follow-up.
The staff performing the health examination and
growth measurements were blind with regard to
randomization allocation. All staff were trained in
performing the measurements according to best practice
and the health examinations were conducted by a
trained pediatrician. For ethical reasons the mother was
not blinded with regard to randomization allocation, but
the staff assessing outcome was blinded, and we find it
unlikely that this would have influenced the outcome
assessment on growth.
When conducting a large number of tests there is
always a risk of chance findings. Therefore, we also con-
ducted permutation tests. We found that MUAC at
24 months overall as well as for girls and for children
Fig. 1 Flowchart
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who had received placebo in the NVAS trial remained
significantly larger in the early MV group after controlling
for multiple testing.
Consistency with other studies
To our knowledge this study is the first to assess the effect
of an early, additional dose of MV on growth. Although
we did not find any consistent effects of an early MV with
growth, we did see a beneficial effect on MUAC at
24 months, especially among girls receiving early MV in
the dry season and among those who received placebo
NVAS.
MUAC is a valid measure of nutritional status and a
good predictor of mortality [16, 19]. The finding that early
MV had a positive effect on MUAC among girls at
24 months corresponds with previous studies from the
same trial concluding that the effects of early MV were
strongest among girls. Thus, mortality and hospital admis-
sion rates were significantly lower among girls [8, 10].
Significantly larger MUAC was seen in relation to dry
season and girls, and in relation to girls and placebo
NVAS at 24 months.
However, the lower mortality in the intervention group
may have biased the later comparisons of growth.
Because those children who died in the control group
may have had poorer growth, which would have caused
a greater difference in the compared outcomes between
the intervention group and the control group if they had
survived. Nevertheless, as we adjusted all analyses for
baseline growth parameters this bias may only have had
limited effect on the results.
Interpretation
It is possible that an early MV can lead to better nutri-
tional status (higher MUAC) and hereby explain the
reduction in mortality seen. However, as the children
generally were not malnourished (MUAC at enrollment,
mean: 14.2 cm, SD (12)), this does not seem likely.
Rather, children who experience repeated infections fail
to thrive and children with repeated infections generally
have poorer nutritional status [20, 21]. Hence, the higher
MUAC is probably a result of less infection in the inter-
vention group. The reason why MUAC is the only
parameter affected, could be that it is a more sensitive
measure compared to e.g., length, why small changes
can be observed [22]. It is also known that MUAC is just
as good or even better way of predicting mortality [23].
We have previously reported that NVAS at birth may
interact with vaccines given later [8, 24]. In regard to
early MV we found that NVAS abrogated the beneficial
effect of early MV on mortality and this may also be the
case for growth. However, the difference in MUAC
between the two groups was relatively small (around
0.1 cm) and is seen only at 24 months, and the question
is, if this makes a big difference in relation to health. It is
likely to confirm that an early MV to a lesser extent influ-
ences growth. We have previously observed more benefi-
cial effects of MV in females and in the dry season. We
have no good explanation for this finding but speculate
that MV may protect against certain seasonal pathogens,
which may be more frequent in females, explaining why
girls receiving early MV in the dry season have better
growth than girls receiving early MV in the rainy season.
Table 1 Effect of an early MV on anthropometric measures at 9 and 24 months of age1
All Boys Girls
Early MV MV Difference1
(CI: 95%)
Early MV MV Difference1
(CI: 95%)
Early MV MV 9 Difference1
(CI: 95%)
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (n) Mean (n)
ALL 9 MONTHS OF AGE
1960 3666 998 1826 962 1840
WAZ (weight-for-age,
z-score)
−0.31(1.19) −0.33(1.16) 0.01(−0.03;0.04) −0.40(1.21) −0.34(1.19) −0.02(−0.07;0.04) −0.22(1.16) −0.31(1.13) 0.03(−0.02;0.08)
LAZ (length-for-age,
z-score)
−0.53(1.25) −0.52(1.22) −0.01(−0.06;0.04) −0.61(1.26) −0.61(1.24) −0.03(−0.10;0.05) −0.45(1.23) −0.44(1.20) 0.00(−0.07;0.08)
MUAC (mid upper arm
circumference, cm)
14.55(1.24) 14.53(1.26) 0.00(−0.04;0.05) 14.71(1.24) 14.75(1.23) −0.01(−0.08;0.06) 14.39(1.23) 14.32(1.26) 0.01(−0.05;0.08)
ALL 24 MONTHS OF AGE
1478 2788 735 1394 743 1394
WAZ (weight-for-age,
z-score)
−0.68(1.02) −0.68(1.03) 0.01(−0.04;0.06) −0.77(1.03) −0.71(1.06) −0.01(−0.08;0.05) −0.59(1.02) −0.64(0.98) 0.03(−0.04;0.10)
LAZ (length-for-age,
z-score
−1.01(1.14) −1.01(1.13) 0.01(−0.05;0.07) −1.12(1.14) −1.11(1.15) −0.02(−0.11;0.06) −0.90(1.13) −0.91(1.10) 0.03(−0.05;0.12)
MUAC (mid upper arm
circumference, cm)
15.14(1.11) 15.06(1.13) 0.08(0.02;0.14)* 15.19(1.08) 15.18(1.15) 0.05(−0.04;0.13) 15.09(1.14) 14.94(1.09) 0.12(0.03;0.20)*
*Significant (P < 0.05) after controlling for multiple testing using the permutation test
1Statistical test was linear regression controlled for weight/length/MUAC at inclusion
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Fig. 2 Effect of an early MV on anthropometric measures stratified by season (a) and NVAS (b) at 24 months2. 2) Statistical test was linear
regression comparing early MV/No early MV controlled for weight/length and MUAC at inclusion. Horizontal lines defines the 95% confidence
interval. *Marks significant effect of early MV (p < 0.05). bMUAC (mid upper arm circumference). # Significant (p < 0.05) after controlling for multiple
testing using the permutation test
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Conclusion
According to current understanding, a vaccine only pro-
tects against a specific pathogen. The findings that an
early additional MV is associated with lower mortality
and lower risk of hospital admission against non-measles
related infections, especially respiratory infections, ques-
tions this paradigm and has pointed to a new under-
standing of vaccines. The evidence for non-specific
effects of vaccines has recently been reviewed by WHO
[25] and it was concluded that more research is needed,
also into the potential biological mechanisms behind
the non-specific effects. This study suggests that the
non-specific effects of the MV are mainly seen on mortality
and hospital admissions and to a lesser extent or not at all
on growth.
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